Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.69 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.69 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.68 |
| ▸ | PPARG | P37231 | 7/20 | 0.68 |
| ▸ | PPARD | Q03181 | 7/20 | 0.68 |
| ▸ | PPARA | Q07869 | 7/20 | 0.68 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.68 |
| ▸ | TSHR | P16473 | 4/20 | 0.68 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | TLR2 | O60603 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | FABP4 | P15090 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.68 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | ESR1 | P03372 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5878982 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL27917702 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL28767027 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL2113762 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL5879015 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL5879088 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL27917758 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL5878798 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL626863 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL3620453 | 1.00 | FFAR4 (0.69) | FFAR4FFAR1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2023-09-07 | — | — | US | disclosed |
| EP-3666778-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA THERAPEUTICS INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-11090319-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2020-07-16 | — | — | US | disclosed |
| EP-3666778-A1 | A CRYSTALLINE CYCLIC BORONIC ACID ESTER DERIVATIVE, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10639318-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | REMPEX PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| EP-3412676-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190076449-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2019-03-14 | — | — | US | disclosed |
| US-10183034-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | REMPEX PHARMACEUTICALS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| EP-3412676-A1 | METHOD FOR THE PREPARATION OF CYCLIC BORONIC ACID ESTER DERIVATIVES | Rempex Pharmaceuticals, Inc. (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20180214465-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2018-08-02 | — | — | US | disclosed |
| EP-2603514-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-10004758-B2 | Cyclic boronic acid ester derivatives and methods of making the same | REMPEX PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180071325-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHODS OF MAKING THE SAME | MELINTA SUBSIDIARY CORP. | 2018-03-15 | — | — | US | disclosed |
| US-9694025-B2 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160220591-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA SUBSIDIARY CORP. | 2016-08-04 | — | — | US | disclosed |
| EP-2814483-A2 | METHODS OF TREATING BACTERIAL INFECTIONS | Rempex Pharmaceuticals, Inc. (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013122888-A2 | METHODS OF TREATING BACTERIAL INFECTIONS | REMPEX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2603514-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021455-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214465-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | FFAR4 2554/4885FFAR1 1899/4885GPR84 3014/4885 |
| US-10183034-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | FFAR4 2554/4885FFAR1 1899/4885GPR84 3014/4885 |
| US-20160220591-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BCL9 | FFAR4 2040/4885FFAR1 1281/4885GPR84 2042/4885 |
| US-20180071325-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHODS OF MAKING THE SAME | BCL6B, BCL6, BCR | FFAR4 1873/4885FFAR1 1279/4885GPR84 3546/4885 |
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | FFAR4 2554/4885FFAR1 1899/4885GPR84 3014/4885 |
| US-10639318-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | FFAR4 2554/4885FFAR1 1899/4885GPR84 3014/4885 |
| US-20190076449-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | FFAR4 2554/4885FFAR1 1899/4885GPR84 3014/4885 |
| US-11090319-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | FFAR4 2554/4885FFAR1 1899/4885GPR84 3014/4885 |
| US-10004758-B2 | Cyclic boronic acid ester derivatives and methods of making the same | BCL6B, BCL6, BCR | FFAR4 1873/4885FFAR1 1279/4885GPR84 3546/4885 |
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | FFAR4 2554/4885FFAR1 1899/4885GPR84 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.